

Executive Corridor
Darlington Memorial Hospital
Hollyhurst Road
Darlington
DL3 6HX
Switchboard Tel: 01325 38 0100
Foundation Trust Office: 01325 74 3625
Corporate Records Office: 01325 74 3700

Request for Information Reference: 06.22.25

FOI Direct line: 01325 743700
Email: cdda-tr.cddftfoi@nhs.net

Email only

20th June 2022

Freedom of Information Act 2000 – Request for Information

Thank you for submitting a request for information which we received on 13th June 2022 in relation to County Durham and Darlington NHS Foundation Trust (the Trust). Your request has been processed under the provisions of the Freedom of Information Act 2000 and I am now able to provide you with a response.

Your request was in relation to lung cancer treatment and I am providing the following information in response to your specific questions:

The below data covers the period from March 2022 – May 2022.

1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Afatinib - 1
- Alectinib - 3
- Amivantamab - 0
- Atezolizumab monotherapy - 18
- Atezolizumab with chemotherapy - 2
- Brigatinib - 0
- Ceritinib - 0
- Crizotinib - 1
- Dacomitinib - 2
- Dabrafenib with Trametinib - 0
- Durvalumab - 12
- Erlotinib - 0
- Gefitinib - 0

- Lorlatinib - 1
- Mobocertinib - 0
- Nintedanib with Docetaxel - 0
- Nivolumab - 0
- Osimertinib - 7
- Pembrolizumab monotherapy - 39
- Pembrolizumab with chemotherapy - 9
- Pemetrexed with Carboplatin/Cisplatin - 0
- Sotorasib - 6
- Tepotinib - 0
- Vinorelbine with Carboplatin/Cisplatin - 0
- Any other active systemic anti-cancer therapy (SACT) - 18
- Palliative care only - 0

2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:

- Atezolizumab monotherapy
- Atezolizumab with chemotherapy
- Durvalumab
- Nivolumab
- Osimertinib
- Pembrolizumab (Keytruda) Mono
- Pembrolizumab (Keytruda) with Chemotherapy
- Tepotinib
- Other active systemic anti-cancer therapy (SACT)
- Palliative care only

Please refer to question 1. The Trust does not centrally record the information broken down by squamous/non-squamous as requested, and estimates that it would take a significant amount of time to gather this data. In order to gather this information it would require a member of staff to manually examine the patient files to distinguish between squamous and non-squamous. Therefore, we are refusing this section of your request for information pursuant to section 12 of the Act on the grounds that we estimate that the cost of complying with the request would exceed the appropriate limit. The appropriate limit at the present time is £450.00 which equates to eighteen hours of work by a member of staff at the rate of £25 per hour.

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log on the Trust's website. However please be assured that we anonymise all responses prior to adding them to the disclosure log.

I hope that this response has provided you with the information you had requested. If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me by telephone or in writing. If however, you are dissatisfied with the way in which your request has been handled and would like an internal review, you will need to contact me in writing at the above address or via cdda-tr.cddftfoi@nhs.

If you remain dissatisfied with our response following an internal review you have the right to appeal to The Information Commissioner at Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. More information is available on their website; www.ico.gov.uk.

Yours sincerely

Corporate Records and Freedom of Information Facilitator